Blinatumomab for severe childhood lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a drug called blinatumomab for children with active lupus that hasn't improved with standard treatments. It aims to see if this immunotherapy can help calm the immune system and reduce lupus activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 5 years old and diagnosed with lupus.
- Your lupus must still be active (SLEDAI score of 6 or higher) despite trying at least three standard treatments.
- You must have a positive antibody test (like ANA or anti-dsDNA) in the last year.
- Your blood counts and organ function must meet specific minimum levels.
- You cannot have certain other conditions or infections, like active tuberculosis or hepatitis B.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called blinatumomab for children with a kidney condition that doesn't respond to standard treatments. It aims to see if it can help when other drugs have failed or caused side effects.
This study looks at how a treatment called CD3xCD19 BiTE affects the immune system of children with lupus that hasn't gotten better with standard medicines. It uses leftover blood samples to learn more about why some children don't respond to usual treatments.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This trial tests a new type of cell therapy, called BCMA/CD70 CAR-T, for children with lupus that hasn't improved with standard treatments. The goal is to see if it can safely reduce disease activity.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
This trial tests a treatment plan that uses blinatumomab (a drug that helps your immune system attack leukemia cells) combined with your own stem cell transplant. It is for people with B-ALL who cannot or choose not to have a transplant from another person.
Hear when a new Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.